Differential expression and cross-talk of peroxisome proliferator-activated receptor γ and retinoid-X receptor α in urothelial carcinomas of the bladder

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 740-745

  Petta, Evrydiki ^a   Sotiropoulou Bonikou, G ^a   Kourelis, K ^a   Melachrinou, M ^a   Bonikos, D S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bladder urothelial carcinomas; Immunohistochemistry; PPAR ; RXR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEOPLASM; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PPAR GAMMA; PROGNOSIS; RETINOID X RECEPTOR ALPHA; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 78651381780     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hevener AL, He W, Barak Y et al. Muscle-specific PPARγ deletion causes insulin resistance. Nat Med 2003; 9, 1491-1497.
2. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122-1128.
3. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid -activated transcription factor. Cell 1995; 79: 1147-1456.
4. Barak Y, Nelson MC, Ong ES et al. PPAR gamma is required for placental, cardiac, and adipose tissue development Mol Cell 1999; 4: 585-595.
5. Rosen ED, Sarraf P, Troy AE et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-617.
6. Druker BJ, Lydon NB. Lessons learned from the development of an Ab1 tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
7. Girnun G, Sarraf P, Mueller E, Droris A, Gonzalez F, Spiegelman B. The role of PRAR-γ as a tumor suppressor gene in colon carcinogenesis. Keystone symposium,2001: The PPARs: A Transcription Odyssey (abstr 332).
8. Saez E, Rosenfeld J, Livolsi A et al. PPARγ signaling exacerbates mammary gland tumor development. Genes Dev 2004; 18: 528-540.
9. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol Med 2001; 7: 395-400.
10. Bourguet W, Andry V, Iitis C et al. Heterodimeric complex of RAR and RXR nuclear receptor ligand-binding domains: purification, crystallization, and preliminary X-ray diffraction analysis. Protein Expr Purif 2000; 19: 284-288.
11. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001; 11: 33-38.
12. Leblanc BP, Stunnenberg HG. 9-cis retinoic acid signaling: changing partners causes some excitement. Genes Dev 1995; 9: 1811-1816.
13. Schulman IG, Shao G, Heyman RA. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function. Mol Cell Biol 1998; 18: 3483-3494.
14. Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol Endocrinol 2002; 16: 707-721.
15. Warrell RP Jr, Frankel SR, Miller WH Jr et al. Differentiation therapy of acute promyelocyte leukemia with tretinoin (alltrans-retinoicacid). N Engl JMed 1991; 324: 1385-1393.
16. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-1039.
17. Zhang W, Rashid A, Wu H, Xu XC. Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues. J Cancer Res Clin Oncol 2001; 127: 237-242.
18. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
19. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-530.
20. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12,14- prostaglandin J2. J Biol Chem 1999; 274: 17042-1708.
21. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-470.
22. Kubota T, Koshizuka K, Williamson EA et al. Ligand for peroxisome proliferator-activated receptor gamma (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
23. Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998; 4: 1046-1052.
24. Varley CL, Stahlschmidt J, Wen-Chun L et al. Pole of PPARg and EGFR signaling in the urothelial terminal differentiation programme. J Cell Sci 2004; 117: 2029-2036.
25. Guan Y-F, Zhang Y-H, Breyer RM, Davis L, Breyer D. Expression of peroxisome proliferator-activated receptor g (PPARg) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-339.
26. Nakashiro KI, Hayashi Y, Kita A et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159: 591-597.
27. Mylona E, Giannopoulou I, Diamantopoulou K et al. Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: Association with differentiation, proliferation and clinical outcome. EJSO 2009; 35: 197-201.
28. Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 2006; 4: 159-167.
29. Tannehill-Gregg SH, Sanderson TP, Minnema D et al. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci 2007; 98: 258-270.
30. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl (butyl) nitrosamine-induced urinary bladder cancers. Int J Cancer 2008; 123: 2254-2259.
31. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92: 418-423.
32. Konopleva M, Elstner E, McQueen TJ et al. Peroxisome proliferator- activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 2004; 3: 1249-1262.
33. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004; 4: 465-477.